mGlu5 receptor antagonists and their therapeutic potential
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Glutamate mediates its effects via ionotropic and metabotropic glutamate (mGlu) receptors. mGlu receptors are G protein-coupled receptors that are classified into three clusters, group I-III. This review focuses on the mGlu5 receptors of group I. mGlu5 receptors are highly expressed in limbic brain regions and are located postsynaptically. Objective: Following the discovery of the prototypical negative allosteric modulator MPEP, the therapeutic potential of mGlu5 receptors has been steadily explored and expanded. This review highlights present developments in drug discovery and the therapeutic potential of negative allosteric modulators. Methods: Material evaluated ranged from patents to published literature, but also included information that is available from public-accessible websites. Results/conclusion: Based on the wide and consistent effects of prototypical antagonists, such as MPEP, it is concluded that mGlu5 receptor antagonists have treatment potential for both peripheral and central nervous system disorders ranging from psychiatric, neurological to neuromuscular, including illnesses with no apparent nervous system link, such as cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725 · cited 16×
“Glatthar R, Troxler TJ. Novartis, Switzerland.”
InfluentialSuppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521 · cited 1×
“In models of secondary generalized seizures, such as 6-Hz-electroshock model of partial seizures in mice and amygdala kindling in rats, MTEP was without effect [195] , but substantially reduced the number of seizures in the fmr 1tm1Cgr , a method representing one aspect of fragile-X syndrome (see later) [196] .”
MethodPorter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308
Self-citationLong term motor complications of levodopa: clinical features, mechanisms, and management strategies
Thanvi, B. R., & Lo, T. C. N. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2003.013912 · Cited by 194
Therapeutic implications of the mGluR theory of fragile X mental retardation
Bear, M. F. (2005) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2005.00135.x · Cited by 137 · cited 4×
“The latter hypothesis was put forward by Bear and colleagues at special meetings at Cold Spring Harbor and has gained substantial attention and influence [207] .”
BackgroundInfluential
Cited by
Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185660 · Cited by 118
Self-citationLindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222463 · Cited by 107
Self-citationMetabotropic glutamate receptor 5 as drug target for Fragile X syndrome
Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.004 · Cited by 106
Self-citationBrief Report: Acamprosate in Fragile X Syndrome
Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0988-9 · Cited by 67
Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501642c · Cited by 66
Self-citation
Metadata
- Authors
- Jaeschke, G., Wettstein, J. G., Nordquist, R. E., & Spooren, W.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2008-02
- Volume
- 18
- Issue
- 2
- Pages
- 123-142
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W1986434830
- Cited by
- 59
- References
- 6
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: mGlu5 receptor antagonists and their therapeutic potential. https://app.cochat.ai/papers/10.1517/13543776.18.2.123
- The paper
- Jaeschke, G., Wettstein, J. G., Nordquist, R. E., & Spooren, W. (2008). mGlu5 receptor antagonists and their therapeutic potential. Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.18.2.123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.